Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00412581
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00411593
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00411632
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
BATTLE Program: Sorafenib in Patients With NSCLC
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT00411671
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
Not Applicable
Completed
- Conditions
- NauseaSarcomaVomiting
- Interventions
- Drug: Palonosetron - Single DoseDrug: Palonosetron - Triple DoseDrug: AdriamycinDrug: Ifosfamide chemotherapy (AI)Drug: ZinecardDrug: MesnaDrug: VincristineDrug: Dexamethasone
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1
Completed
- Conditions
- LeukemiaLymphomaMyeloma
- Interventions
- Drug: BusulfanDrug: GemcitabineDrug: MelphalanOther: Hematopoietic Cell TransplantationDrug: Rituximab for Patients with B-Cell MalignanciesDrug: Palifermin
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT00410982
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: RituximabBiological: Sargramostim (GM-CSF)
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00411086
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Wild Type p53 Adenovirus for Oral Premalignancies
Phase 1
Terminated
- Conditions
- Mouth Cancer
- Interventions
- Genetic: INGN 201
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00410865
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT00410059
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- Drug: ZD6474
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00410189
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath